Physician profile
Robert E Dematteo
NPI 1083610125
$3,284.16
in general payments reported to CMS, 2019-2025
24 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $446 · 2021: $298 · 2022: $576 · 2023: $151 · 2024: $89.50 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $727.76 | 2019 | |
| Allergan, INC. | $431.47 | 2019-2020 | |
| Boston Scientific Corporation | $384.59 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $247.09 | 2019-2025 | Trelegy Ellipta, Nucala |
| Amarin Pharma, INC. | $202.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $192.26 | 2020-2025 | Airsupra, Breztri |
| Genzyme Corporation | $125.72 | 2023-2025 | |
| Ardelyx, INC. | $117.01 | 2025 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $87.73 | 2019 | |
| Abbvie INC. | $87.43 | 2021-2023 | Vraylar |
| Pfizer INC. | $82.75 | 2020-2022 | |
| Daiichi Sankyo INC. | $78.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.47 | 2022 | |
| Merck Sharp & Dohme LLC | $43.59 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $41.80 | 2020 | |
| Gilead Sciences, INC. | $38.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.42 | 2022 | |
| Amgen INC. | $23.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.02 | 2023 | |
| Biogen, INC. | $21.38 | 2021 | |
| Mylan Specialty L.P. | $16.41 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $14.76 | 2019 | |
| Lilly USA, LLC | $13.60 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dematteo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.